DK3897655T3 - 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser - Google Patents
3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser Download PDFInfo
- Publication number
- DK3897655T3 DK3897655T3 DK19831675.4T DK19831675T DK3897655T3 DK 3897655 T3 DK3897655 T3 DK 3897655T3 DK 19831675 T DK19831675 T DK 19831675T DK 3897655 T3 DK3897655 T3 DK 3897655T3
- Authority
- DK
- Denmark
- Prior art keywords
- 17alpha
- 3beta
- pregn
- benzyloxy
- methyl
- Prior art date
Links
- IFFPDWXBMZYJMH-DFTYQABXSA-N 1-[(3S,8R,9S,10R,13S,14S,17S)-10,13,17-trimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(C)C(=O)C)CC1=CC=CC=C1 IFFPDWXBMZYJMH-DFTYQABXSA-N 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3897655T3 true DK3897655T3 (da) | 2024-09-23 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19831675.4T DK3897655T3 (da) | 2018-12-18 | 2019-12-18 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12583884B2 (da) |
| EP (2) | EP3669876A1 (da) |
| JP (1) | JP7515480B2 (da) |
| KR (1) | KR102845328B1 (da) |
| CN (1) | CN113260366B (da) |
| AU (1) | AU2019409912B2 (da) |
| BR (1) | BR112021011654A2 (da) |
| CA (1) | CA3118210C (da) |
| CL (1) | CL2021001458A1 (da) |
| DK (1) | DK3897655T3 (da) |
| ES (1) | ES2987823T3 (da) |
| FI (1) | FI3897655T3 (da) |
| HR (1) | HRP20241376T1 (da) |
| HU (1) | HUE068626T2 (da) |
| IL (1) | IL284032B2 (da) |
| LT (1) | LT3897655T (da) |
| MA (1) | MA54518B1 (da) |
| MD (1) | MD3897655T2 (da) |
| MX (1) | MX2021006904A (da) |
| PL (1) | PL3897655T3 (da) |
| PT (1) | PT3897655T (da) |
| RS (1) | RS66013B1 (da) |
| SI (1) | SI3897655T1 (da) |
| SM (1) | SMT202400425T1 (da) |
| WO (1) | WO2020127468A1 (da) |
| ZA (1) | ZA202103284B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211704A1 (es) | 2018-12-18 | 2021-09-01 | Merck Sharp & Dohme | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih |
| JPWO2024085245A1 (da) | 2022-10-21 | 2024-04-25 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234125A1 (en) * | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| ATE496894T1 (de) | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CA2694264A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| PL2709631T3 (pl) * | 2011-05-20 | 2017-07-31 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Antagoniści receptora cb1 |
| ES2621528T3 (es) | 2012-11-28 | 2017-07-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de 3-(4-sustituido)-bencil éter de pregnenolona |
| RS60295B1 (sr) * | 2013-03-19 | 2020-07-31 | Univ Pompeu-Fabra | Antagonisti kanabionoidnih receptora cb1 za upotrebu u lečenju oboljenja vezanih za abnormalnosti neuronskih dendrita |
| MA51891B1 (fr) | 2018-02-20 | 2024-03-29 | Aelis Farma | 3bêta-(4-methoxybenzyloxy)pregn-5-en-20-one pour une utilisation dans le traitement des troubles liés aux cannabinoïdes |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3743070T3 (da) | Forbindelser til behandling af kinaseafhængige lidelser | |
| DK3673080T3 (da) | Antisense-oligomerer til behandling af lidelser og sygdomme | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3429571T3 (da) | Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3512517T3 (da) | Anvendelse af pridopidin til behandling af angst og depression | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3934637T3 (da) | (n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3724173T3 (da) | Forbindelser til behandling af neuromuskulære lidelser | |
| EP3655036C0 (en) | COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS | |
| IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
| DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| DK3432895T3 (da) | Blodpladepelletlysat til anvendelse til behandling af neurologiske forstyrrelser | |
| EP3532063C0 (en) | POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| EP3661492C0 (en) | NITROSYNAPSIN FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER | |
| DK3448382T3 (da) | Arimoclomol til behandling af glucocerebrosidase-associerede lidelser | |
| DK3897578T3 (da) | Dosisregimer til anvendelse af ly3154207 ved behandling af dopaminerge cns-lidelser | |
| DK3897655T3 (da) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |